NTHL1 and cancer: The bi-allelic mutation was confirmed in the breast and colorectal cancers from the homozygous carrier, however, there was no evidence of loss of the wild type allele or a second point mutation in NTHL1 in any cancers from heterozygous germline variant carriers.